NAV Growth
Growth of each fund's NAV over the selected period, rebased to 0%
-
-
-
1M
3M
6M
1Y
3Y
5Y
Fund Details
| Fund Details | HDFC Pharma and Healthcare Fund - Direct (G) | SBI Healthcare Opportunities Fund - Direct (G) |
|---|---|---|
| Fund Type | Equity | Equity |
| Risk | Very High | Very High |
| Min SIP Amount | ₹100 | ₹500 |
| Min Lumpsum | ₹100 | ₹5,000 |
| Expense Ratio | 1.08% | 1.04% |
| NAV | ₹22.61 (25 Sept 2026) | ₹604.52 (25 Sept 2026) |
| Fund Size | ₹3,310.64 Cr | ₹5,796.42 Cr |
| Fund Started | 04 Oct 2023 | 02 Jan 2013 |
| Lock-in Period | No lock-in | No lock-in |
| Exit Load |
Returns
| Returns | HDFC Pharma and Healthcare Fund - Direct (G) | SBI Healthcare Opportunities Fund - Direct (G) |
|---|---|---|
| 1M | 2.74% | 1.82% |
| 3M | 9.11% | 8.14% |
| 6M | 30.24% | 26.08% |
| 1Y | 28.36% | 22.78% |
| 3Y | — | 24.99% |
| 5Y | — | 18.70% |
| Since Inception | 31.73% |
Risk Ratios
Trailing risk-adjusted performance measures
| Risk Ratio | HDFC Pharma and Healthcare Fund - Direct (G) | SBI Healthcare Opportunities Fund - Direct (G) |
|---|---|---|
| Alpha | 24.17 | 17.41 |
| Beta | 0.66 | 0.64 |
| Sharpe | 1.58 | 1.27 |
| Standard Deviation | 4.68 | 4.16 |
Holding Analysis
| Holding Analysis | HDFC Pharma and Healthcare Fund - Direct (G) | SBI Healthcare Opportunities Fund - Direct (G) |
|---|---|---|
| Top 5 Holdings | 30.66% | 35.04% |
| Top 10 Holdings | 48.86% | 55.99% |
| Portfolio Turnover | 34.76 | 0.36 |
| Equity | 98.42% | 96.79% |
| Debt | 1.83% | 4.16% |
| Cash | — | — |
Top Holdings
HDFC Pharma and Healthcare Fund - Direct (G)
Fund Manager
| Fund Manager | HDFC Pharma and Healthcare Fund - Direct (G) | SBI Healthcare Opportunities Fund - Direct (G) |
|---|---|---|
| Name | , |
About Fund
| About | HDFC Pharma and Healthcare Fund - Direct (G) | SBI Healthcare Opportunities Fund - Direct (G) |
|---|---|---|
| AMC | HDFC Mutual Fund | SBI Mutual Fund |
| Scheme Category | Sectoral Fund | Sectoral Fund |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch Date | 14 Sept 2023 | 01 Jan 2013 |

